View source for Classifying aging as a treatable condition

= Why Classifying Aging as a Treatable Condition Matters for Longevity Research and Policy =

'''Classifying aging as a treatable condition''' is a question about paperwork that decides real outcomes. Medicine runs on codes, indications, and endpoints. A code tells record systems what to count. An indication tells a regulator what a drug is for. An endpoint tells a trial what counts as success. This page serves the futurism and abundance side of this wiki, and it treats longevity as a policy and research fight. Its argument is that the public quarrel over whether aging is a disease is mostly a quarrel over the wrong word, and that the practical levers sit in codes, indications, and accepted measures of decline.

''This page is general information for learning and research, not medical or legal advice.''

For the biology of aging, see [[Aging|Aging]]. For how to read claims about specific interventions, see [[How to evaluate claims about anti-aging treatments|Evaluating anti-aging claims]]. For the rate idea behind the goal of defeating aging, see [[Longevity escape velocity|Longevity escape velocity]].

== The angle in one sentence ==
The disease label that some longevity advocates wanted has been withdrawn, but the function based wording that replaced it, together with regulator rules on composite outcomes and surrogate endpoints, may be a more usable foothold for aging research than the label itself.

== What happened in ICD-11 ==
The International Classification of Diseases is the common language used to record and compare health data across hospitals and countries. For ICD-11, the WHO had proposed including the term old age under code MG2A, a category of symptoms, signs, or clinical findings not elsewhere classified.<ref name="lancetedit">[https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(22)00154-4/fulltext The Lancet Healthy Longevity. Is ageing a disease? Editorial, 2022.]</ref> According to the World Health Organization, this category exists for quality control. It lets coders record unclear statements that physicians write on death certificates or medical records. The category has been in place for 50 years, and old age had replaced its earlier label, senility, because that word had gained a negative connotation.<ref name="whofaq">[https://www.who.int/standards/classifications/frequently-asked-questions/old-age World Health Organization. Old age. ICD frequently discussed topics.]</ref>

Clinicians and advocacy groups objected that old age as a diagnosis was ageist and could cause harm. One group proposed frailty as a better defined clinical entity instead.<ref name="banerjee">[https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00201-4/fulltext Banerjee D, et al. Not a disease. A global call for action urging revision of the ICD-11 classification of old age. The Lancet Healthy Longevity, 2021.]</ref> Researchers on the other side wrote that MG2A reflected a shift from chronological to biological age and would encourage therapies aimed at aging mechanisms.<ref name="bischof">[https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00303-2/fulltext Bischof E, et al. Advanced pathological ageing should be represented in the ICD. The Lancet Healthy Longevity, 2022.]</ref> After a meeting with the ICD-11 committee in October 2021, the category was retitled Ageing associated decline in intrinsic capacity, and the word pathological in the XT9T extension code for ageing was replaced with biological.<ref name="rabheru">[https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(22)00102-7/fulltext Rabheru K, Byles JE, Kalache A. How old age was withdrawn as a diagnosis from ICD-11. The Lancet Healthy Longevity, 2022.]</ref> The WHO now keeps old age for indexing only, so coders can still be guided when a physician writes it.<ref name="whofaq" /> A mirror of the ICD-11 index lists MG2A under the new title, with entries such as age related frailty and senescence.<ref name="cismef">[https://www.cismef.org/page/detail/en/ICD11_CA_835503193 CISMeF. Ageing associated decline in intrinsic capacity, ICD-11 category MG2A.]</ref>

== Why intrinsic capacity is the overlooked part ==
It is easy to read the new wording as a defeat for the idea of treating aging. A closer reading suggests otherwise. The WHO defines intrinsic capacity as all the mental and physical capacities a person can draw on, including the ability to walk, think, see, hear, and remember. It also says the level of intrinsic capacity is influenced by diseases, injuries, and age related changes.<ref name="whoha">[https://www.who.int/news-room/questions-and-answers/item/healthy-ageing-and-functional-ability World Health Organization. Healthy ageing and functional ability. Questions and answers, 2020.]</ref> That is a description of something measurable that can rise or fall. The authors who pushed for the change argued that it moves attention from a static label to a dynamic assessment, with room for prediction and prevention.<ref name="rabheru" />

A category built on measured decline in walking, thinking, and memory is closer to the language a trial needs than a category built on a birthday. Whether anyone can turn it into an accepted trial outcome is an open research question, not a settled fact.

== The regulator side ==
Coding is only half the story. In the United States a drug is approved for an indication, and the basic regulatory picture is covered on the claims page linked above. What matters here is the list of problems the National Institute on Aging says geroscience drugs raise when sponsors approach the FDA. Geroscience is the field built on the premise that drugs aimed at aging mechanisms could prevent or treat several age related conditions at once. The NIA names three novel issues. The first is defining the indication and context of use, since a drug acting on aging mechanisms might be proposed for very wide use while its balance of risk and benefit differs between people. The second is the use of multiple, composite, or global outcomes, such as all cause mortality or physical disability. The third is the role of biomarkers and surrogate endpoints, because aging mechanisms may take decades to produce clinical effects.<ref name="nia">[https://www.nia.nih.gov/research/information-fda-review-geroscience-related-ind-applications National Institute on Aging. Information on FDA review of geroscience related IND applications.]</ref>

The TAME trial (Targeting Aging with Metformin) is described as a pioneering attempt to work inside these rules. Its planners consulted the FDA and chose a composite endpoint of time to onset of major diseases such as heart attack, stroke, heart failure, cancer, mild cognitive impairment or dementia, or death. A 2022 review reports that the FDA would not accept the trial's biomarker data as the primary basis for approval. The same review points out that a design which waits for diseases to appear cannot test a preventive drug given decades earlier.<ref name="spr">[https://sciencepolicyreview.pubpub.org/pub/as1jqcrr Kalafut K, Janes M, Riccio-Ackerman F. The future of treating aging. MIT Science Policy Review, 2022.]</ref> The status of the trial is tracked on the [[Longevity escape velocity|Longevity escape velocity]] page.

== Surrogate endpoints are the real bottleneck ==
The FDA sorts surrogate endpoints into candidate, reasonably likely, and validated. A validated surrogate needs strong evidence that changing it predicts a specific clinical benefit, and blood pressure as a stand in for stroke is the FDA's own example. Between 2010 and 2012 the FDA approved 45 percent of new drugs based on a surrogate endpoint. Reasonably likely surrogates can support accelerated approval, which the FDA describes as a program for patients with serious diseases.<ref name="fdasur">[https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development U.S. Food and Drug Administration. Surrogate Endpoint Resources for Drug and Biologic Development.]</ref>

This is where classification returns. If faster review paths are tied to serious disease, then a drug meant for people who are aging but not yet diagnosed with anything has no obvious fit. That is an interpretation, not an FDA statement, and it is the kind of gap that policy work could test. A validated measure of aging related decline would let trials run in smaller groups over shorter periods, much as blood pressure did for stroke prevention. Without one, every aging trial must wait for people to get sick.

== The spending argument ==
The Centers for Disease Control and Prevention reports that 90 percent of the nation's 5.3 trillion dollars in annual health care spending goes to people with chronic and mental health conditions.<ref name="cdc">[https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html Centers for Disease Control and Prevention. Fast Facts. Health and Economic Costs of Chronic Conditions. 2026.]</ref> Age is recognized as a primary risk factor for many prominent chronic diseases, including heart disease and cancer.<ref name="spr" /> If a classification change and an accepted endpoint made it possible to test interventions that delay several of these diseases together, the payoff would show up where spending is heaviest, in years of very poor health and the end of life. The data on how spending concentrates in those years, and the counterpoint that longer lives can add costs, are covered in [[The economics of extending healthy lifespan|Healthy lifespan economics]].

The stigma side has a price as well. The WHO reports that ageism is associated with earlier death by 7.5 years, and that in the United States one in every seven dollars spent on the eight most expensive conditions was due to ageism, about 63 billion dollars in total.<ref name="whoageism">[https://www.who.int/news-room/questions-and-answers/item/ageing-ageism World Health Organization. Ageing. Ageism. Questions and answers.]</ref> A label that deepens ageism could raise costs while a better endpoint lowers them. Any honest version of the spending argument has to count both.

== Arguments against the disease label ==
The strongest objections come from geriatric medicine. A Lancet Healthy Longevity editorial listed four. Aging happens to everyone, while a disease affects only some. Aging is varied and partly plastic, so chronological age is a poor marker of risk. Calling aging a disease may worsen ageism. And no intervention has yet been clinically shown to slow the rate of aging in humans.<ref name="lancetedit" /> Other critics point to medicalization. If aging is a disease, then simply staying alive makes everyone sick, and older adults could be deprioritized for care. Supporters reply that progeria in children is recognized as a disease, and that obesity gained disease codes because it clusters with other conditions.<ref name="spr" />

Readers who follow debates about labels in mental health will notice a familiar pattern. A diagnostic label can open doors to funding and payment while also changing how a person is seen and treated. The [[Critical views of mental illness|Critical views]] page covers that wider debate.

== Limits of this argument ==
Several parts of the case are weak or uncertain. No validated surrogate endpoint for aging exists today, so the path described here depends on research that may fail. The claim that intrinsic capacity could become a trial outcome is this page's interpretation, not a position taken by the WHO or the FDA. The accelerated approval point is also an interpretation. The ICD-11 entry was checked through a mirror of the index rather than the WHO browser itself, and code titles can change between releases. Spending figures describe the United States and may not carry over to other health systems. Delaying disease could move costs later rather than remove them. Finally, some researchers argue that the label debate is a distraction and that science can proceed without any reclassification.<ref name="spr" />

== What citizens, researchers, and students can do ==
Policy literacy here means knowing the difference between a code, an indication, and an endpoint, and asking which one a proposal actually changes. Researchers can study whether measures of walking, cognition, vision, hearing, and memory predict later chronic disease well enough to serve as surrogates. Students can trace how one ICD category moved from senility to old age to its current title, and what each change was meant to do. Citizens can follow the ICD proposal platform, where the change to the old age category began as a submitted proposal, and the FDA resources on endpoints cited below.<ref name="whofaq" />

A concrete research question for readers: could a measured decline in intrinsic capacity serve as an accepted outcome in a trial of an intervention targeting aging, and what evidence would show that slowing that decline predicts fewer heart attacks, strokes, cancers, and cases of dementia?

==Discussion questions, essay ideas, and learning related AI prompt ideas==
'''Discussion questions'''
* Does the word disease matter for funding and payment, or do codes, indications, and endpoints matter more?
* Why might geriatricians and longevity researchers disagree about ICD-11 while wanting the same healthy years for older people?
* Should a regulator approve a drug for people with no diagnosed disease if it delays several diseases at once?

'''Essay ideas'''
* Trace the history of ICD category MG2A from senility to old age to its current title and explain what each change was meant to fix.
* Argue for or against intrinsic capacity as a trial outcome for interventions that target aging.
* Compare the health costs of ageism with the possible savings from delaying chronic disease.

'''Learning related AI prompt ideas'''
* Explain the difference between a diagnostic code, a drug indication, and a trial endpoint using one example of each.
* Describe the three levels of surrogate endpoints the FDA uses and give a known example of a validated one.
* Help me design a study that tests whether decline in walking speed and memory predicts later chronic disease.
* Summarize the main arguments for and against calling aging a disease, with one source for each side.

== See also ==
* [[Aging|Aging]]
* [[Longevity escape velocity|Escape velocity]]
* [[Longevity escape velocity as a policy target|Longevity policy target]]
* [[The economics of extending healthy lifespan|Healthy lifespan economics]]
* [[How to evaluate claims about anti-aging treatments|Evaluating anti-aging claims]]
* [[Anti-aging research|Anti-aging research]]
* [[Biomedical gerontology|Biomedical gerontology]]
* [[Abolishing aging|Abolishing aging]]
* [[Medical ethics|Medical ethics]]
* [[Epidemiology|Epidemiology]]
* [[Post-scarcity economy|Post-scarcity economy]]

== References ==
<references />

[[Category:Aging]]
[[Category:Life extension]]
[[Category:Public health]]
[[Category:Policy]]